Global Human Microbiome Market Overview
The key drivers impacting the human microbiome market are rising gut-related disorders like inflammatory bowel disease (IBD), irritable bowel syndrome, Crohn's disease, etc., due to constantly changing lifestyle and food habits. For instance, As per the International Foundation for Functional Gastrointestinal Disorders, About 10 to 15 percent of people worldwide suffer from IBS in a year. In that percentage, around 45 million people with IBS live in the United States. In 2015, an estimated 1.3% of US adults (3 million) reported being diagnosed with IBD (either ulcerative colitis or Crohn's disease). This was a considerable increase from 1999 (0.9% or 2 million adults). These escalating cases of gut-related disease lead to growing research are likely to develop colossal market demand. Moreover, the increasing development of human microbiome-based tests for early disease detection & diagnosis contributes to human microbiome market demand in the later years.
According to Value Market Research, the global human microbiome market size was valued at about USD 326.01 million in 2020 and is estimated to grow at a CAGR of around 22% during the forecast period 2021 to 2027.
The rising focus on human microbiome research and therapeutics development will likely augment the need for the human microbiome in the forecast period. For instance, the National Institutes of Health (NIH) provides widespread support for human microbiome research. Around 21 of 27 NIH Institutes and Centers (ICs) are currently funding this area through their extramural research programs. The NIH program objectives and the resources developed had invested $215 M in the Human Microbiome Project (HMP) program during 2007–2016. However, the limitation in offering the causal link between diseases and dysbiosis s hamper the market in the long run. In addition, a dearth of expertise and inadequate research impedes market growth. Nevertheless, the market trends, increase in the funding initiatives, and government programs to support the efforts of pharmaceutical companies for the development of the novel drug might provide massive market opportunities to the market's key players.
The human microbiome market is widespread, with many local and international players. The market leaders follow diverse strategies to strengthen their market, such as extending product portfolio, acquisitions, contracts, amalgamation, product upgrades to raise their market share globally. The key players in the report are Embion Technologies S.A, ENTEROME SA, Evelo Biosciences Inc., IGEN BIOLAB GROUP, 4D Pharma Plc., Ferring Pharmaceuticals, Gnubiotics Sciences, YSOPIA Bioscience, ViThera Pharmaceuticals Inc., Gnubiotics Sciences, Osel Inc., SECOND GENOME THERAPEUTICS, Immuron Ltd., OxThera AB, AOBiome, Vedanta Biosciences, Inc., Seres Therapeutics, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., and Assembly Biosciences, Inc.
In this research report, the human microbiome market is segmented by product, disease, application, technology type, metabolomics, and region.
Analysis by Product:
By product, the report is divided into probiotics, prebiotics, diagnostic tests, drugs, and other products. The drugs segment dominates the product segment with the largest market share in 2020. It is increasing the number of human microbiome-based drug products in clinical trials. Moreover, rising funding to develop microbiome-based drugs contributes to the growth of the drugs segment growth in the forecast period.
Analysis by Disease:
By disease, the report is divided into infectious diseases, endocrine and metabolic disorders, gastrointestinal diseases, cancer, and other diseases (cardiovascular diseases, neurological disorders, dermatology diseases, immune-modulated disorders, and hematological disorders. The infectious diseases segment dominates the diseased segment with the largest market share in 2020. It is due to the rising cognizance of the ill effects of antibiotic use on the natural flora (such as disruptions) that has highlighted the need for specific bacterial-targeted therapy for infectious diseases. Moreover, the growing incidence of infections due to microbial dysbiosis and the increasing number of clinical trials for developing target-specific microbiome-based therapies contribute to the growth of the infectious diseases segment growth in the forecast period.
Analysis by Application:
By application, the report is segmented into therapeutics and diagnostics. The therapeutics segment dominates with the highest market share in 2020. It is due to the increase in funding for R&D into microbiome-based therapies worldwide. Moreover, technological advancements, the increasing number of clinical trials for the diagnostics segment, and growing collaborations between key market players and research institutes contributed to the growth of the therapeutics segment in the coming years.
Analysis by Technology Type:
By technology type, the report is segmented into genomics, proteomics, sequencing, and metabolomics. The Genomics segment dominates the technology type segment with the highest share in 2020. It is due to the growing research and development in the field of genomics all across the globe. Moreover, the rising funding program by the several countries government to support the genomics research contributes to the remarketing and value recovery segment's growth in the forecast period.
Analysis by Region:
In the regional prospect of the global human microbiome market, the North America region dominates with the largest market share of 42% in 2020. It is due to the rise in the incidences of lifestyle-related diseases and autoimmune disorders and rising awareness on preventive healthcare. Moreover, the availability of funding for microbiome research and the increasing number of microbiome research & clinical activities contribute to the tremendous market growth across North America.
Market Segmentation covered in the Report:
By Product
- Probiotics
- Prebiotics
- Diagnostic Tests
- Drugs
- Other Products
By Disease
- Infectious Diseases
- Endocrine and Metabolic Disorders
- Gastrointestinal Diseases
- Cancer
- Other Diseases (Cardiovascular Diseases, Neurological Disorders, Dermatology Diseases, Immune-Modulated Disorders, and Hematological Disorders.)
By Application
By Technology Type
- Genomics
- Sequencing
- 16s rRNA sequencing method
- Whole-genome sequencing method
- Other Sequencing methods (shotgun metagenomic sequencing, transcriptomics, and targeted sequencing.)
- Other Genomic Technologies (Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays)
- Proteomics
- Metabolomics
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.